## Yongzhong Hou

## List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/8148204/yongzhong-hou-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

32 657 15 25 g-index

32 856 ext. papers ext. citations avg, IF L-index

#	Paper	IF	Citations
32	EGFR/PPAR/HSP90 pathway mediates cancer cell metabolism and chemoresistance. <i>Journal of Cellular Biochemistry</i> , <b>2021</b> , 122, 394-402	4.7	4
31	CD47/SIRP[pathway mediates cancer immune escape and immunotherapy. <i>International Journal of Biological Sciences</i> , <b>2021</b> , 17, 3281-3287	11.2	3
30	AMPK phosphorylates PPARIto mediate its stabilization, inhibit glucose and glutamine uptake and colon tumor growth. <i>Journal of Biological Chemistry</i> , <b>2021</b> , 297, 100954	5.4	3
29	Role of autophagy on cancer immune escape. Cell Communication and Signaling, 2021, 19, 91	7.5	6
28	PD-L1 degradation pathway and immunotherapy for cancer. Cell Death and Disease, 2020, 11, 955	9.8	30
27	Identification of potential novel biomarkers to differentiate malignant thyroid nodules with cytological indeterminate. <i>BMC Cancer</i> , <b>2020</b> , 20, 199	4.8	6
26	PPARlis a regulator of autophagy by its phosphorylation. <i>Oncogene</i> , <b>2020</b> , 39, 4844-4853	9.2	7
25	DPEP1 promotes the proliferation of colon cancer cells via the DPEP1/MYC feedback loop regulation. <i>Biochemical and Biophysical Research Communications</i> , <b>2020</b> , 532, 520-527	3.4	1
24	PPAR agonist alleviates tumor growth and chemo-resistance associated with the inhibition of glucose metabolic pathway. <i>European Journal of Pharmacology</i> , <b>2019</b> , 863, 172664	5.3	4
23	Metformin inhibits PPARIagonist-mediated tumor growth by reducing Glut1 and SLC1A5 expressions of cancer cells. <i>European Journal of Pharmacology</i> , <b>2019</b> , 857, 172425	5.3	12
22	Inhibition of Autophagy Alleviates Cadmium-Induced Mouse Spleen and Human B Cells Apoptosis. <i>Toxicological Sciences</i> , <b>2019</b> , 170, 109-122	4.4	16
21	PPAR agonist enhances colitis-associated colorectal cancer. <i>European Journal of Pharmacology</i> , <b>2019</b> , 842, 248-254	5.3	16
20	PPAR Enhances Cancer Cell Chemotherapy Sensitivity by Autophagy Induction. <i>Journal of Oncology</i> , <b>2018</b> , 2018, 6458537	4.5	5
19	HBXIP activates the PPARINF-B feedback loop resulting in cell proliferation. <i>Oncotarget</i> , <b>2018</b> , 9, 404-4	13.3	4
18	PPARIpromotes tumor progression via activation of Glut1 and SLC1-A5 transcription. <i>Carcinogenesis</i> , <b>2017</b> , 38, 748-755	4.6	23
17	PPARIPromotes Cancer Cell Glut1 Transcription Repression. <i>Journal of Cellular Biochemistry</i> , <b>2017</b> , 118, 1556-1562	4.7	15
16	BRAF-activated non-protein coding RNA (BANCR) advances the development of esophageal squamous cell carcinoma via cell cycle. <i>Open Life Sciences</i> , <b>2017</b> , 12, 128-134	1.2	

## LIST OF PUBLICATIONS

15	Peroxisome proliferator-activated receptors (PPARs) are potential drug targets for cancer therapy. <i>Oncotarget</i> , <b>2017</b> , 8, 60704-60709	3.3	55
14	INGs are potential drug targets for cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , <b>2017</b> , 143, 189-197	4.9	12
13	Naoxintong/PPAR Signaling Inhibits Cardiac Hypertrophy via Activation of Autophagy. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2017</b> , 2017, 3801976	2.3	10
12	EGFR/MDM2 signaling promotes NF-B activation via PPARIdegradation. Carcinogenesis, 2016, 37, 215-22	<b>23</b> .6	15
11	Inhibitor of growth-4 is a potential target for cancer therapy. <i>Tumor Biology</i> , <b>2016</b> , 37, 4275-9	2.9	5
10	Naoxintong/PPARlsignaling Inhibits H9c2 Cell Apoptosis and Autophagy in Response to Oxidative Stress. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2016</b> , 2016, 4370381	2.3	7
9	PPARIregulates tumor progression, foe or friend?. European Journal of Pharmacology, 2015, 765, 560-4	5.3	18
8	Ubiquitin-mediated NFB degradation pathway. Cellular and Molecular Immunology, 2015, 12, 653-5	15.4	24
7	PPARlinduces cell apoptosis by destructing Bcl2. <i>Oncotarget</i> , <b>2015</b> , 6, 44635-42	3.3	23
6	PPARIsignaling regulates colorectal cancer. <i>Current Pharmaceutical Design</i> , <b>2015</b> , 21, 2956-9	3.3	24
5	PPAR against tumors by different signaling pathways. <i>Onkologie</i> , <b>2013</b> , 36, 598-601		26
4	PPARIs an E3 ligase that induces the degradation of NFB/p65. <i>Nature Communications</i> , <b>2012</b> , 3, 1300	17.4	165
3	Entamoeba histolytica cysteine proteinase 5 binds integrin on colonic cells and stimulates NFkappaB-mediated pro-inflammatory responses. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 35497-504	5.4	75
2	Simultaneous knockdown of p18INK4C, p27Kip1 and MAD1 via RNA interference results in the expansion of long-term culture-initiating cells of murine bone marrow cells in vitro. <i>Acta Biochimica Et Biophysica Sinica</i> , <b>2008</b> , 40, 711-720	2.8	2
1	Bcl2 impedes DNA mismatch repair by directly regulating the hMSH2-hMSH6 heterodimeric complex. <i>Journal of Biological Chemistry</i> , <b>2007</b> , 282, 9279-87	5.4	41